Patents by Inventor Roberta FORESTI

Roberta FORESTI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CARBON MONOXIDE-RELEASING MOLECULE (CORM) OR COMPOSITION THEREOF FOR USE IN THE TREATMENT OR THE PREVENTION OF AN INTESTINAL DYSBIOSIS IN A SUBJECT
    Publication number: 20250295626
    Abstract: The invention concerns a carbon monoxide-releasing molecule (CORM) or composition thereof for use in the treatment or the prevention of an intestinal dysbiosis in a subject. More particularly, the invention concerns a carbon monoxide-releasing molecule (CORM) or composition thereof for use in the treatment or the prevention of an intestinal dysbiosis, preferably a caecum and/or colon dysbiosis in a subject, wherein the carbon monoxide-releasing molecule or composition thereof is administered orally.
    Type: Application
    Filed: May 11, 2023
    Publication date: September 25, 2025
    Inventors: Roberto MOTTERLINI, Roberta FORESTI
  • Highly efficient NRF2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
    Patent number: 10519179
    Abstract: The present invention relates to highly efficient Nrf2 activators-CO-releasing molecules of formula (I) and (II) capable of increasing HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases, wherein CORM represents a carbonyl metal complex chosen from among: Mn(CO)5, formula (III), (IV), (V), (VI), (VII), (VIII) and (IX).
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 31, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Roberto Motterlini, Roberta Foresti, Anthony Ollivier, Michael Rivard, Thierry Martens
  • HIGHLY EFFICIENT NRF2 ACTIVATORS-CO-RELEASING MOLECULE HYBRIDS, THEIR USE IN THE TREATMENT OF INFLAMMATORY OR CARDIOVASCULAR DISEASES AND THEIR PROCESS OF PREPARATION
    Publication number: 20180258121
    Abstract: The present invention relates to highly efficient Nrf2 activators-CO-releasing molecules of formula (I) and (II) capable of increasing HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases, wherein CORM represents a carbonyl metal complex chosen from among: Mn(CO)5, formula (III), (IV), (V), (VI), (VII), (VIII) and (IX).
    Type: Application
    Filed: September 23, 2016
    Publication date: September 13, 2018
    Inventors: Roberto MOTTERLINI, Roberta Foresti, Anthony Ollivier, Michael Rivard, Thierry Martens
  • Fumarate-CO-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
    Patent number: 9944669
    Abstract: The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: April 17, 2018
    Assignees: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Roberto Motterlini, Roberta Foresti, Thierry Martens, Michael Rivard
  • FUMARATE-CO-RELEASING MOLECULE HYBRIDS, THEIR USE IN THE TREATMENT OF INFLAMMATORY OR CARDIOVASCULAR DISEASES AND THEIR PROCESS OF PREPARATION
    Publication number: 20170174716
    Abstract: The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.
    Type: Application
    Filed: March 20, 2015
    Publication date: June 22, 2017
    Applicants: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Roberto MOTTERLINI, Roberta FORESTI, Thierry MARTENS, Michael RIVARD